Dr. Reddy’s v. Genentech (24-1978): Federal Circuit Appeal Dismissed in 179 Days
Dr. Reddy’s Laboratories challenged Genentech, Hoffmann-La Roche, and AbbVie before the Federal Circuit over US11110087B2, a patent covering combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor. The parties jointly agreed to dismiss the appeal under Fed. R. App. P. 42(b) — with each side bearing its own costs — closing the proceeding in under six months.
A consensual Federal Circuit exit with no merits adjudication
Filed on 21 June 2024, Case 24-1978 brought Dr. Reddy’s Laboratories, Ltd. before the U.S. Court of Appeals for the Federal Circuit as appellant, with Genentech, Inc., Hoffmann-La Roche AG, Sari L. Heitner Enschede, and AbbVie, Inc. as appellees. The dispute centred on US11110087B2, which protects a combination therapy pairing a type II anti-CD20 antibody — the class covering obinutuzumab — with a selective Bcl-2 inhibitor such as venetoclax, a regimen used in haematologic malignancies including CLL.
On 17 December 2024, the Federal Circuit issued a dismissal order under Federal Rule of Appellate Procedure 42(b), acting on the parties’ agreement. The court made no ruling on the merits of the underlying infringement or validity dispute. Costs were split symmetrically, with each side absorbing its own litigation expenses — a structure consistent with a negotiated resolution rather than a unilateral withdrawal.
The 179-day lifespan of this appeal is notably short for Federal Circuit proceedings, suggesting the parties reached whatever agreement underpinned this dismissal relatively quickly after docketing. The public record does not disclose the terms of any underlying commercial arrangement, licensing negotiation, or settlement. The validity and enforceability of US11110087B2 therefore remain judicially unresolved at the appellate level, leaving the patent’s scope a live question for third-party biosimilar developers and competitors in the anti-CD20 oncology space.
Filing to Case Dismissed in 179 days
179-day appeal duration — from filing to Federal Circuit dismissal order
Appeal dismissed by agreement: what the Fed. R. App. P. 42(b) order means
Fed. R. App. P. 42(b): a consensual procedural exit, not a merits ruling
Rule 42(b) permits the parties to a federal appeal to jointly request dismissal at any time. The Federal Circuit’s order here reflects that agreement — the court made no finding on the validity or infringement of US11110087B2. The underlying dispute is extinguished at this appellate level without any precedential determination, meaning neither party obtained a court ruling they could cite against the other in future proceedings.
No merits adjudicationDr. Reddy’s exits without a ruling — rights and risks preserved
As appellant, Dr. Reddy’s obtained no Federal Circuit ruling in its favour on the patent’s validity or on infringement. However, by agreeing to dismissal it also avoided an adverse merits decision that could have strengthened the patent. The symmetric costs order suggests neither side accepted liability. Whether Dr. Reddy’s secured commercial concessions — e.g. a licence or market-entry agreement — is not disclosed in the public record.
No adverse merits rulingGenentech, Roche, and AbbVie retain an unadjudicated patent
The patent holders avoid the risk of Federal Circuit invalidation, but equally obtain no appellate affirmance of US11110087B2’s validity. The patent remains enforceable on its face, but its scope was never tested at this level. Future challengers — including other biosimilar or generic developers — will face a patent whose appellate history signals a willingness to negotiate rather than litigate to judgment.
Patent status unresolvedCombination oncology patents: enforcement uncertainty persists
US11110087B2 covers a commercially significant regimen in haematological oncology. A dismissal at this level — without merits — leaves biosimilar and generic entrants without a definitive validity ruling to rely on. Companies developing obinutuzumab or venetoclax-class therapies should treat this patent as live and subject to enforcement, while noting that the dispute’s swift resolution may signal room for licensing negotiations with the patent holders.
Enforce risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Dr. Reddy’s Laboratories, Ltd. | Company | Indian pharmaceutical group asserting rights over anti-CD20/Bcl-2 combination therapy patent US11110087B2Search in Eureka ↗ |
| Defendant | Genentech, Inc. | Company | Genentech/Roche-led oncology patent holders and AbbVie, co-defendants in the Federal Circuit appealSearch in Eureka ↗ |
| Co-Defendant | HOFFMAN-LA ROCHE AG | Company | Search in Eureka ↗ |
| Co-Defendant | SARI L. HEITNER ENSCHEDE | Individual | Search in Eureka ↗ |
| Co-Defendant | AbbVie, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Dufresne | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Autumn N. Nero | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Brandon Michael White | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan Irvin Tietz | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Nathan K. Kelley | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Perkins Coie LLP | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Chad Peterman | Attorney | Counsel for Genentech, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Zeilberger | Attorney | Counsel for Genentech, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric William Dittmann Esq. | Attorney | Counsel for Genentech, Inc.Search in Eureka ↗ |
| Defendant counsel | Katherine A. Daniel | Attorney | Counsel for Genentech, Inc.Search in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for Genentech, Inc.Search in Eureka ↗ |
| Defendant counsel | Scott Frederick Peachman | Attorney | Counsel for Genentech, Inc.Search in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing Genentech, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order is strictly procedural: acting on the parties’ joint agreement, the court dismissed the appeal under Fed. R. App. P. 42(b) and directed each side to bear its own costs. No standard of review was applied, no claim construction reviewed, and no validity or infringement determination was made. The order carries no precedential weight on the merits of US11110087B2. The symmetric costs allocation is notable — it is inconsistent with a unilateral capitulation by either party and more consistent with a negotiated resolution, though the specific terms remain undisclosed.
US11110087B2 — Type II Anti-CD20 & Selective Bcl-2 Inhibitor Combination Therapy
US11110087B2 (application no. US17/187,468) protects a combination therapy pairing a type II anti-CD20 monoclonal antibody — the class typified by obinutuzumab — with a selective Bcl-2 inhibitor such as venetoclax. This regimen targets the apoptosis pathway in B-cell malignancies, including chronic lymphocytic leukaemia (CLL) and other haematologic cancers. The patent reflects a clinically validated therapeutic strategy that has become a standard-of-care approach in haematological oncology, lending it significant commercial and exclusivity value.
For biosimilar and generic pharmaceutical developers seeking to enter the anti-CD20 or Bcl-2 inhibitor market, US11110087B2 represents a potentially blocking patent at the combination-therapy level even where the individual antibody or small molecule components may be separately available. The involvement of Genentech (Roche) and AbbVie — whose portfolios span obinutuzumab and venetoclax respectively — signals a layered IP landscape around this regimen. Any competitor commercialising a type II anti-CD20/Bcl-2 inhibitor combination should conduct a thorough FTO analysis against this patent and its family members.
Should you run an FTO against US11110087B2?
Yes — if your pipeline includes any combination regimen pairing a type II anti-CD20 antibody with a Bcl-2 inhibitor, US11110087B2 is a material FTO consideration. This applies to biosimilar developers targeting obinutuzumab-class antibodies, companies developing next-generation Bcl-2 inhibitors, and any oncology platform exploring combination immunotherapy in CLL or related haematologic indications. The patent is held by a coalition of major biologics players with demonstrated enforcement intent.
PatSnap Eureka’s FTO Search Agent can map US11110087B2’s claim scope against your specific product candidate, identify continuation applications and family members in key jurisdictions, and flag prosecution history estoppel that may limit or expand the claims. Eureka’s landscape analytics can also surface competing patents from Roche, Genentech, and AbbVie that may interact with the combination therapy space — giving your IP and R&D teams a consolidated risk picture before clinical or commercial investment decisions.
Run a freedom-to-operate analysis on US11110087B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in oncology biologics and antibody combination therapy
Federal Circuit appeals involving anti-CD20 antibody patents and Bcl-2 inhibitor combination therapy — related cases, outcomes, and enforcement trends.
What this case signals for the oncology biologics IP landscape
A Federal Circuit dismissal without merits keeps the combination therapy patent in play — and raises questions for every biosimilar developer watching this space.
No Federal Circuit ruling means US11110087B2 is still fully enforceable
The appeal’s dismissal under Rule 42(b) leaves US11110087B2 intact and unreviewed at the appellate level. Any company developing a type II anti-CD20 and Bcl-2 inhibitor combination therapy must treat this patent as an active enforcement risk. A validity challenge at the PTAB or in district court remains available but carries its own litigation cost and timing implications.
Symmetric cost-sharing is a key settlement signal in Federal Circuit appeals
When each side bears its own costs on dismissal, it typically signals a negotiated resolution rather than a simple withdrawal. Patent attorneys monitoring biosimilar entry disputes should note that the Genentech/Roche/AbbVie alliance demonstrated willingness to resolve — potentially through licensing — rather than pursue a merits outcome, which may inform negotiation strategy for third-party challengers.
Dr. v Genentech — key questions answered
The appeal was dismissed on 17 December 2024 under Federal Rule of Appellate Procedure 42(b) by agreement of the parties, with each side bearing its own costs. The Federal Circuit made no ruling on the merits of the infringement or validity dispute concerning US11110087B2. The case lasted 179 days from filing to dismissal.
US11110087B2 (application US17/187,468) protects a combination therapy using a type II anti-CD20 antibody — such as obinutuzumab — together with a selective Bcl-2 inhibitor such as venetoclax. This regimen is a clinically validated approach in haematologic malignancies including CLL. Genentech, Hoffmann-La Roche, and AbbVie are among the parties with interests in this IP, reflecting the patent’s significance across the biologics and oncology small-molecule sectors.
A Rule 42(b) dismissal is purely procedural and carries no merits determination. The Federal Circuit did not review or rule on the validity, enforceability, or infringement scope of US11110087B2. The patent remains in force and its claims have not been judicially limited or invalidated at the appellate level. Future challengers cannot rely on this dismissal as precedent on the merits.
The case record lists Hoffmann-La Roche AG, AbbVie, Inc., and Sari L. Heitner Enschede as co-defendants alongside Genentech, Inc. This suggests overlapping patent ownership or licensing interests in US11110087B2 across the Roche/Genentech group and AbbVie, whose venetoclax portfolio intersects with the Bcl-2 inhibitor component of the claimed combination. The precise ownership structure of the patent is not detailed in the public docket.
An order that each side bears its own costs on dismissal is inconsistent with a straightforward capitulation by Dr. Reddy’s. In Federal Circuit practice, such cost-splitting typically accompanies a negotiated resolution — whether a licence, market-entry agreement, or other commercial arrangement. The specific terms, if any, are not disclosed in the public record and would not appear on the court docket under a Rule 42(b) dismissal.
PatSnap Eureka searches patents and litigation data to answer instantly.